Detalhe da pesquisa
1.
Sequential Lateral Lymphatic Metastasis Shows Similar Oncologic Outcomes to Upward Spread in Advanced Rectal Cancer After Preoperative Chemoradiotherapy.
Dis Colon Rectum
; 67(3): 359-368, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37962146
2.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
; 27(2): 375-386, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38281295
3.
Bemarituzumab plus mFOLFOX6 as first-line treatment in East Asian patients with FGFR2b-overexpressing locally advanced or metastatic gastric/gastroesophageal junction cancer: subgroup of FIGHT final analysis.
Gastric Cancer
; 2024 Jun 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38861192
4.
Preoperative sequential short-course radiation therapy and FOLFOX chemotherapy versus long-course chemoradiotherapy for locally advanced rectal cancer: a multicenter, randomized controlled trial (SOLAR trial).
BMC Cancer
; 23(1): 1059, 2023 Nov 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923987
5.
Oncological impact of intraperitoneal chemotherapy after cytoreductive surgery for patients with colorectal peritoneal metastasis: A bi-institutional retrospective analysis.
J Surg Oncol
; 127(4): 668-677, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36515216
6.
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Oncology (Williston Park)
; 37(4): 176-183, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37104758
7.
KEYSTEP-008: phase II trial of pembrolizumab-based combination in MSI-H/dMMR metastatic colorectal cancer.
Future Oncol
; 19(37): 2445-2452, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37701986
8.
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Gastric Cancer
; 25(3): 609-618, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35015188
9.
Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study.
Gastric Cancer
; 25(1): 170-179, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34476643
10.
Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Gastric Cancer
; 25(1): 207-217, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34480657
11.
Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.
Gastric Cancer
; 25(6): 1039-1049, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35920999
12.
Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Gastric Cancer
; 24(4): 946-958, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33743112
13.
Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer.
Int J Colorectal Dis
; 36(6): 1279-1286, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33547945
14.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32653053
15.
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Gastric Cancer
; 23(1): 143-153, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087200
16.
A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data.
Gastric Cancer
; 23(3): 510-519, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31863227
17.
Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma.
Int J Mol Sci
; 20(6)2019 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30875759
18.
Quercetin Synergistically Inhibit EBV-Associated Gastric Carcinoma with Ganoderma lucidum Extracts.
Molecules
; 24(21)2019 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-31653035
19.
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 390(10111): 2461-2471, 2017 Dec 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28993052
20.
Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
Br J Cancer
; 117(12): 1753-1760, 2017 Dec 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29073638